Therapeutic potential of Adiponectin and AdipoRon in Duchenne Muscular Dystrophy

Abstract

Adiponectin (ApN) is a hormone known to possess powerful anti-inflammatory effects on various tissues, including the skeletal muscle. Duchenne Muscular Dystrophy (DMD) is the most devastating type of muscular dystrophy. Although dystrophin mutations represent the primary cause of DMD, it is the secondary processes involving persistent inflammation and subsequent impaired regeneration that likely exacerbate disease progression. This work highlights the involvement of ApN as well as an agonist of its receptors, AdipoRon, in DMD. We show that ApN and AdipoRon markedly reduce inflammation and muscle damage while improving strength and myogenesis in a mouse model of DMD. This protection is mainly ascribed to the activation of APMK pathway after binding to AdipoR1, ApN muscle receptor. This study may offer new promising therapeutic prospects for the management of muscle inflammatory disorders and myopathies.(BIFA - Sciences biomédicales et pharmaceutiques) -- UCL, 201